Committed to care
Navigating the reimbursement process for Aquadex can be simplified with the right support. Our team is dedicated to helping you understand and appropriately code your reimbursement options for this advanced fluid management therapy.
Outpatient Ultrafiltration for Fluid Overload
A cost-effective approach to fluid management for patients and providers
Maximize the economic impact
The SmartFlow® System has demonstrated economic benefits by reducing heart failure admissions and readmissions, and shortening the average length of stay, which can lead to substantial cost savings.1 2025 reimbursement changes further enhance it economic viability.
- Code Reassignment
From APC 5241 to higher-paying APC 5242 for outpatient Aquadex services. - Cost Savings
Lowers healthcare costs while maintaining quality care.2 - Improved Patient Experience
Provides treatment in scheduled, more comfortable settings.
Explore Patient Pathways
Discover the benefits of outpatient care with Aquadex therapy as an alternative to traditional inpatient diuretic treatments. Our side-by-side comparison highlights the advantages of Aquadex in managing fluid overload with fewer hospital stays, providing a direct route to improved patient outcomes and satisfaction.
Discover the Outpatient Advantage
Our case studies reveal the transformative effects Aquadex therapy can have in outpatient settings, emphasizing its clinical efficacy and economic advantages.
Learn how transitioning to Aquadex can lead to significant improvements in patient management and substantial reductions in healthcare costs.
CASE STUDY: The Christ Hospital Health Network3
A prospective, single-center study of 23 patients treated with the Aquadex FlexFlow® System to manage heart failure (HF) related fluid overload in an outpatient setting
Results:
CASE STUDY: The Ohio State University Wexner Medical Center in Columbus, OH4
A retrospective, single-center analysis of 14 patients treated with the Aquadex FlexFlow® System to manage heart failure (HF) patients in an outpatient setting in order to avoid hospital admissions
Results:
Conclusions:
Outpatient UF can be performed successfully with a favorable safety profile in appropriately-selected patients while providing adequate treatment for mild to moderate ADHF.
“We believe the use of outpatient UF may reduce the number of unplanned admissions for this high-risk population.” — Dr. Sitaramesh Emani, The Christ Hospital
Reach out today to get started
Reimbursement Quick Reference Guide
Aquadex® Reimbursement Code is: 0692T
0692T can be used to report the Aquadex procedure in all settings of care
Questions?
Contact Your Nuwellis Representative
OR
Nuwellis Customer Service
Phone: 1-855-786-2778
Email: support@nuwellis.com
The service is available Monday – Friday from 8:00am – 5:00pm CST
1 O’Brien et al; A Prospective Study of Serial Outpatient Aquapheresis; Journal of Cardiac Failure; Volume 19, Issue 8, Supplement, 2013; ISSN 1071-9164
2 Costanzo MR, Fonarow GC, Rizzo JA. Ultrafiltration versus diuretics for the treatment of fluid overload in patients with heart failure: a hospital cost analysis. J Med Econ. 2019 Jun;22(6):577-583.
3 O’Brien et al; A Prospective Study of Serial Outpatient Aquapheresis; Journal of Cardiac Failure; Volume 19, Issue 8, Supplement, 2013; ISSN 1071-9164
4 Emani S, et al. Poster from The 16th Annual Scientific Meeting of HFSA. 2012.
Nuwellis provides this information for your convenience and for educational purposes only. It does not constitute legal advice or a recommendation regarding clinical practice or how-to code, complete, bill, or submit any particular claim for payment. Information provided is gathered from third-party sources and is subject to change without notice due to frequently changing laws, rules, and regulations. Nuwellis disclaims any responsibility for claims submitted by providers. The provider has the sole responsibility to determine medical necessity and to submit appropriate codes and charges that accurately describe the service provided to a patient based on a patient’s medical condition. The information provided in this summary is not a guarantee of coverage in any individual case. The key in all coding and billing to payers is to be truthful and not misleading and make full disclosures to the payer about the product and the procedures associated with its use when seeking reimbursement for any product or procedure. Providers should follow payer-specific billing and coding requirements and contact the payer if they have questions. Nuwellis makes no guarantee that the use of this information will prevent differences of opinion or disputes with Medicare or other payers as to the correct form of billing or the amount that will be paid to providers of service. Please note that the existence of a code for a procedure does not guarantee coverage or payment. Where reimbursement is sought for use of a product that may be inconsistent with, or not expressly specified in, the FDA cleared or approved labeling (e.g., instructions for use, operator’s manual or package insert), consult with your billing advisors or payers on handling such billing issues. Some payers may have policies that make it inappropriate to submit claims for such items or related services.
